delF508-cystic fibrosis transmembrane conductance regulator correctors (Novartis/Novartis Inst Functional Genomics)

N/A

Report date: 2025/03/18 18:19:02
NME

Base Information

Drug NamedelF508-cystic fibrosis transmembrane conductance regulator correctors (Novartis/Novartis Inst Functional Genomics)
Drug Alias NameCFTR chloride channel modulators (Novartis)delF508 CFTR mutation correctors (Novartis/Novartis Inst Functional Genomics)CFTR correctors (Novartis)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCystic fibrosis transmembrane conductance regulator modulators
TargetsCystic fibrosis transmembrane conductance regulator
Therapy Area/IndicationsCystic Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Institutes For Biomedical Research Inc
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Institutes For Biomedical Research IncGenomics Institute of the Novartis Research Foundation
Inactive CompaniesN/A
Active IndicationsCystic Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A